University Home | Medical Center Home

Home | Faculty | Resources | For Patients | Contact Us

 

Department Faculty

Frank S. Lieberman, MD

Associate Professor of Neurology and Medical Oncology
Director,
Adult Neurooncology Program, UMPC Cancer Center
Clinical Phone: (412) 692-4724
Academic Phone: (412) 648-6507

Specialized Areas of Interest

Cancer.

Biography

Dr. Lieberman is director of the adult neurooncology program at UPMC Cancer Centers. His clinical and research efforts in 2006 encompassed both the treatment of primary CNS tumors and the neurological complications of cancer. Brain tumor translational investigations focus on the application of molecular genetic techniques and functional imaging techniques to develop strategies for individually optimized molecularly targeted treatment of patients with malignant gliomas, the most common brain tumors in adults. In collaboration with neuropathologists at UPSOM and the biotechnology company Redpath, Inc, Dr. Lieberman has led the application of microdissection-based genotyping to identifying prognostic subgroups within glioblastoma, anaplastic gliomas and anaplastic oligodendroglioma. This work has established UPMC as a national leader in the use of molecular neuropathology in diagnosis and management of CNS neoplasms.

Dr. Lieberman serves as institutional principal investigator for UPMC in the North American Brain Tumor Consortium and served as national study chair for the NABTC trial of ZD-1839 for recurrent malignant gliomas. He is a member of the CNS tumor committee for the Radiation Therapy Oncology Group, and is currently national study chair of the RTOG trial 04-20 evaluating the regimen of irinotecan and temozolomide as adjuvant therapy of glioblastoma. Dr. Lieberman will be presenting the initial efficacy results of this trial as a platform presentation at the Society for Neurooncology Annual Meeting in November 2006, having previously presented prelimary data for this trial at the American Society for Clincal Oncology meeting in 2006. This trial has established UPMC as a national leader in the RTOG CNS program. In collaboration with Dr. Hideho Okada, MD, PhD, Assistant Professor of Neurosurgery, Dr. Lieberman is a coinvestigator for the institutional gliomas peptide based vaccine trial in patients with recurrent malignant gliomas; one of the first peptide targeted gliomas vaccines to be tested in humans. Dr. Lieberman and collaborators in the Translational Imaging Program in UPCI are studying the effects of molecularly targeted antiangiogenic drugs entering the clinical trials program in an intracranial rat gliomas model using dynamic contrasted enhanced MRI (DCE-MRI) techniques. This information is being used to optimize the design of DCE imaging algorithms for use in the human phase 2 trials of these drugs. With collaborators in Nuclear Medicine and Neuroradiology, Dr. Lieberman is evaluating DCE- MRI, quantitative MR spectroscopy and PET imaging with the novel agent F15-thymidine for noninvasive grading of the malignancy of gliomas, and for utility in predicting tumor response to therapy before a change in size of the tumor.

Dr. Lieberman directs the clinical neurooncology program for UPMC Cancer Center, is director of the neurooncology rotation at UPMC Hillman-Shadyside for neurology residents and fellows and is an attending for Neurology housestaff morning report one day per week. He provides neurooncology consultation service for UPMC Presbyterian, Magee, and Shadyside hospitals. He directs the Neurooncology Tumor Board, a weekly CME category 1 approved academic teaching case management conference, and a monthly Neurooncology Tumor Board conference at UPMC Shadyside which is a case presentation and topic review format for the oncology community. He also serves on the bioethics committee at UPMC Shadyside. Dr. Lieberman is a member of the Society for Neurooncology, and was as a member of the scientific review committee for the 2006 Society of Neurooncology Annual Meeting. He is a member of the American Association of Cancer Researchers, American Society of Clinical Oncology, and the American Academy of Neurology.

Dr. Lieberman's publications can be reviewed through the National Library of Medicine's publication database.

Professional Organization Membership

American Academy of Neurology
Board of Medical Examiners
Radiation Therapy Oncology Group

Dr. Lieberman

Dr. Lieberman